Posts

Showing posts with the label apixaban

atrial fibrillation: stopping anticoagulation 1 yr after ablation

A recent South Korean study found that some patients who had catheter ablation for atrial fibrillation were able to discontinue anticoagulation therapy, in the ALONE-AF trial (Anticoagulation One year after Ablation of Atrial Fibrillation in Patients with Atrial Fibrillation (see afib ablation stop anticoag after 1 yr JAMA2025 in dropbox, or doi:10.1001/jama.2025.14679) Details: -- 850 adults aged 19 to 80 were enrolled in this open-label randomized controlled trial from 2020 the 2023 at 18 hospitals in South Korea, with follow-up until 2025 -- All enrollees had atrial fibrillation (AF) with catheter ablation and were put on anticoagulation as per usual; they were in intermediate or high risk of thromboembolism with a CHA2DS2-VASc score of at least 1 for men or 2 for women -- All had at least one non-sex-related stroke risk factor as determined by their CHA2DS2-VASc score and no documented recurrence of atrial arrhythmia for at least one year after their catheter ablation for AF ...

edoxaban alone is better than with anti-platelet if atrial fibrillation and stable CAD

Image
  a recent randomized control trial found that in patients with stable coronary artery disease and atrial fibrillation (AF), monotherapy with the anticoagulant edoxaban was better than dual antithrombotic therapy with an added antiplatelet drug (see afib and stable CAD NEJM2024  in dropbox, or DOI: 10.1056/NEJMoa2407362)   Details : -- 1040 patients were enrolled in a multicenter, open-label, adjudicator-masked, randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with atrial fibrillation and stable coronary artery disease, in 18 sites in South Korea, with recruitment from  2019-2022     -- coronary artery disease (CAD) was defined as being previously treated with revascularization or managed medically         -- stable CAD was defined as having had a percutaneous coronary intervention (PCI) or CABG at least 6 months before enrollment or an...

atrial fibrillation: treating subclinical AF, new AF guidelines

  A recent article found that short-lasting, asymptomatic intervals of atrial fibrillation (“subclinical atrial fibrillation”)   were  associated with a significantly increased risk of stroke; and apixaban, vs aspirin, was effective in decreasing stroke or systemic embolism, though at a cost of increased bleeding  (see  afib subclinical apix helps NEJM2023  in dropbox, or  DOI: 10.1056/NEJMoa2310234 )   Details : -- 4012 patients from 247 clinical sites  in  16 European and North American countries who had subclinical atrial fibrillation (SCAF) lasting 6 minutes to 24 hours,  as  determined  from  their long-term continuous monitoring with pacemakers or defibrillators, were randomized to apixaban 5 mg twice a day (2.5 mg if indicated) versus aspirin 81 mg daily, in the ARTESIA trial -- eligible participants also a CHA 2 DS 2 -VASc score of at least 3, and subsequent  protocol  amendments raised the minimum a...

Atrial fib: apixaban outperforms rivaroxaban

Image
  A recent large study of Medicare recipients with atrial fibrillation found that rivaroxaban was associated with more ischemic strokes as well as more hemorrhagic events than apixaban   (see   afib apix better than rivarox JAMA2021  in dropbox, or   doi:10.1001/jama.2021.21222 )   Details:  -- retrospective cohort using the US Medicare database of those >65 years old, finding 581,451 patients with atrial fibrillation, newly prescribed rivaroxaban or apixaban, and followed for 4 years; study from 2013-2018 -- mean age 77, 50% female -- CHA 2 DS 2 -VASc scores: mean 4.2 rivaroxaban, 4.4 apixaban -- comorbidities: hypertension 90%, diabetes 35%, heart failure 30%, anemia 26%, COPD 22%, cancer 18%, GI or other bleeding 15%, CKD stage 3 in 16% -- meds: ACE/ARB 62%, PPI 31%, loop diuretic 28%, oral steroids 25%, diltiazem or verapamil 21%, NSAIDs 17% (though they may have also been OTC), platelet inhibitors 16% -- those on rivaroxaban had a more favorabl...